BCL2 and breast carcinoma: During the course of action, these nanomicelles significantly reduce the mitochondrial membrane potential of breast cancer cells, increase the release of cyt c, simultaneously increase the expression of the proapoptotic protein Bax, and reduce the expression of the antiapoptotic protein Bcl-2, thereby enhancing the ability of the drug to promote the apoptosis of tumor cells [70].